Literature DB >> 20160717

Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML.

Yoriko Saito1, Naoyuki Uchida, Satoshi Tanaka, Nahoko Suzuki, Mariko Tomizawa-Murasawa, Akiko Sone, Yuho Najima, Shinsuke Takagi, Yuki Aoki, Atsushi Wake, Shuichi Taniguchi, Leonard D Shultz, Fumihiko Ishikawa.   

Abstract

Cancer stem cells have been proposed to be important for initiation, maintenance and recurrence of various malignancies, including acute myeloid leukemia (AML). We have previously reported that CD34+CD38- human primary AML stem cells residing in the endosteal region of the bone marrow are relatively chemotherapy resistant. Using a NOD/SCID/IL2rgamma(null) mouse model of human AML, we now show that the AML stem cells in the endosteal region are cell cycle quiescent and that these stem cells can be induced to enter the cell cycle by treatment with granulocyte colony-stimulating factor (G-CSF). In combination with cell cycle-dependent chemotherapy, G-CSF treatment significantly enhances induction of apoptosis and elimination of human primary AML stem cells in vivo. The combination therapy leads to significantly increased survival of secondary recipients after transplantation of leukemia cells compared with chemotherapy alone.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20160717      PMCID: PMC3857633          DOI: 10.1038/nbt.1607

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  36 in total

1.  Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches.

Authors:  Tatsuki Sugiyama; Hiroshi Kohara; Mamiko Noda; Takashi Nagasawa
Journal:  Immunity       Date:  2006-12       Impact factor: 31.745

2.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

3.  Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells.

Authors:  Michael F Clarke; John E Dick; Peter B Dirks; Connie J Eaves; Catriona H M Jamieson; D Leanne Jones; Jane Visvader; Irving L Weissman; Geoffrey M Wahl
Journal:  Cancer Res       Date:  2006-09-21       Impact factor: 12.701

Review 4.  Cancer stem cells.

Authors:  Craig T Jordan; Monica L Guzman; Mark Noble
Journal:  N Engl J Med       Date:  2006-09-21       Impact factor: 91.245

5.  In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment.

Authors:  Dorothy A Sipkins; Xunbin Wei; Juwell W Wu; Judith M Runnels; Daniel Côté; Terry K Means; Andrew D Luster; David T Scadden; Charles P Lin
Journal:  Nature       Date:  2005-06-16       Impact factor: 49.962

6.  Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study.

Authors:  Sergio Amadori; Stefan Suciu; Ulrich Jehn; Roberto Stasi; Xavier Thomas; Jean-Pierre Marie; Petra Muus; Francois Lefrère; Zwi Berneman; George Fillet; Claudio Denzlinger; Roel Willemze; Pietro Leoni; Giuseppe Leone; Marco Casini; Francesco Ricciuti; Marco Vignetti; Filip Beeldens; Franco Mandelli; Theo De Witte
Journal:  Blood       Date:  2005-03-10       Impact factor: 22.113

Review 7.  Acute myeloid leukaemia.

Authors:  Elihu Estey; Hartmut Döhner
Journal:  Lancet       Date:  2006-11-25       Impact factor: 79.321

8.  The chemokine GRObeta mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment.

Authors:  Seiji Fukuda; Huimin Bian; Andrew G King; Louis M Pelus
Journal:  Blood       Date:  2007-04-06       Impact factor: 22.113

9.  Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate.

Authors:  Heather G Jørgensen; Mhairi Copland; Elaine K Allan; Xiaoyan Jiang; Allen Eaves; Connie Eaves; Tessa L Holyoake
Journal:  Clin Cancer Res       Date:  2006-01-15       Impact factor: 12.531

10.  Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial.

Authors:  Donald W Milligan; Keith Wheatley; Timothy Littlewood; Jenny I O Craig; Alan K Burnett
Journal:  Blood       Date:  2006-02-16       Impact factor: 22.113

View more
  161 in total

1.  The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation.

Authors:  Benjamin Mizukawa; Eric O'Brien; Daniel C Moreira; Mark Wunderlich; Cindy L Hochstetler; Xin Duan; Wei Liu; Emily Orr; H Leighton Grimes; James C Mulloy; Yi Zheng
Journal:  Blood       Date:  2017-08-04       Impact factor: 22.113

2.  The haematopoietic stem cell niche at a glance.

Authors:  Cristina Lo Celso; David T Scadden
Journal:  J Cell Sci       Date:  2011-11-01       Impact factor: 5.285

3.  Ex vivo expansion of cord blood progenitors impairs their short-term and long-term repopulating activity associated with transcriptional dysregulation of signalling networks.

Authors:  T Holmes; F Yan; K-H Ko; R Nordon; E Song; T A O'Brien; A Dolnikov
Journal:  Cell Prolif       Date:  2012-03-20       Impact factor: 6.831

Review 4.  Targeting leukemic stem cells by breaking their dormancy.

Authors:  Marieke Alida Gertruda Essers; Andreas Trumpp
Journal:  Mol Oncol       Date:  2010-06-09       Impact factor: 6.603

Review 5.  Bone metastasis and the metastatic niche.

Authors:  Guangwen Ren; Mark Esposito; Yibin Kang
Journal:  J Mol Med (Berl)       Date:  2015-08-15       Impact factor: 4.599

6.  The Role of Neutrophils in Measles Virus-mediated Oncolysis Differs Between B-cell Malignancies and Is Not Always Enhanced by GCSF.

Authors:  Aditi Dey; Yu Zhang; Anna Z Castleton; Katharine Bailey; Brendan Beaton; Bella Patel; Adele K Fielding
Journal:  Mol Ther       Date:  2015-08-17       Impact factor: 11.454

7.  Bone marrow microenvironment modulation of acute lymphoblastic leukemia phenotype.

Authors:  Blake S Moses; William L Slone; Patrick Thomas; Rebecca Evans; Debbie Piktel; Peggi M Angel; Callee M Walsh; Pamela S Cantrell; Stephanie L Rellick; Karen H Martin; James W Simpkins; Laura F Gibson
Journal:  Exp Hematol       Date:  2015-09-25       Impact factor: 3.084

Review 8.  Energy metabolism and drug response in myeloid leukaemic stem cells.

Authors:  Alfonso E Bencomo-Alvarez; Andres J Rubio; Mayra A Gonzalez; Anna M Eiring
Journal:  Br J Haematol       Date:  2019-06-24       Impact factor: 6.998

9.  Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma.

Authors:  Osman Cen; Richard Longnecker
Journal:  Mol Cancer Ther       Date:  2011-01-31       Impact factor: 6.261

Review 10.  Multidrug-resistant cancer cells and cancer stem cells hijack cellular systems to circumvent systemic therapies, can natural products reverse this?

Authors:  Qian Zhang; Yunjiang Feng; Derek Kennedy
Journal:  Cell Mol Life Sci       Date:  2016-09-12       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.